{"transactions":[{"id":4636962,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":56623,"kind":"person","name":"COWARD D SCOTT","position":1,"cik":"0001247296","reported_name":"COWARD D SCOTT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2026-10-07T20:06:03.000Z","date":"2026-10-06","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on October 6, 2027, after which 1/48 of the option becomes exercisable on the 6th day of each month thereafter, with the option becoming fully vested on October 6, 2030."}],"balance_after":125000,"derivative":{"exercise_price":0.478,"expiration_date":"2036-10-06","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001247296-26-000005","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000124729626000005/ownership.xml","form_type":"4"}},{"id":4636955,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":184013,"kind":"person","name":"Kuznik Paul Brian","position":1,"cik":"0002156537","reported_name":"Kuznik Paul Brian","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2026-10-07T20:05:04.000Z","date":"2026-10-06","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on October 6, 2027, after which 1/48 of the option becomes exercisable on the 6th day of each month thereafter, with the option becoming fully vested on October 6, 2030."}],"balance_after":125000,"derivative":{"exercise_price":0.478,"expiration_date":"2036-10-06","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0002156537-26-000004","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2156537/000215653726000004/ownership.xml","form_type":"4"}},{"id":4617799,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":20926,"kind":"person","name":"Jones Keith Anthony","position":1,"cik":"0002026411","reported_name":"Jones Keith Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-15T20:05:04.000Z","date":"2026-09-14","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":0.562,"value":5620.0,"ownership":{"direct":true},"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001193125-26-391889","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2026411/000119312526391889/ownership.xml","form_type":"4"}},{"id":679059,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":20926,"kind":"person","name":"Jones Keith Anthony","position":1,"cik":"0002026411","reported_name":"Jones Keith Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-21T20:05:06.000Z","date":"2026-08-20","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":0.693,"value":6930.0,"ownership":{"direct":true},"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001193125-26-361081","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2026411/000119312526361081/ownership.xml","form_type":"4"}},{"id":681739,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":20926,"kind":"person","name":"Jones Keith Anthony","position":1,"cik":"0002026411","reported_name":"Jones Keith Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-19T20:00:03.000Z","date":"2026-08-17","kind":"purchase","planned":false,"acquired":true,"shares":30000,"price":0.594,"value":17820.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.590 to $0.596. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001193125-26-356847","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2026411/000119312526356847/ownership.xml","form_type":"4"}},{"id":740093,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38799,"kind":"person","name":"Windham-Bannister Susan Richards","position":1,"cik":"0001713760","reported_name":"Windham-Bannister Susan Richards","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2026-06-12T22:01:09.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030."}],"balance_after":80000,"derivative":{"exercise_price":1.08,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001104659-26-073620","document":"tm2617880-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000110465926073620/tm2617880-11_4seq1.xml","form_type":"4"}},{"id":740092,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38798,"kind":"person","name":"Constantino Michael T.","position":1,"cik":"0001817285","reported_name":"Constantino Michael T.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2026-06-12T21:59:51.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030."}],"balance_after":80000,"derivative":{"exercise_price":1.08,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001104659-26-073617","document":"tm2617880-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000110465926073617/tm2617880-10_4seq1.xml","form_type":"4"}},{"id":740091,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2026-06-12T21:56:36.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030."}],"balance_after":80000,"derivative":{"exercise_price":1.08,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001104659-26-073614","document":"tm2617880-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000110465926073614/tm2617880-7_4seq1.xml","form_type":"4"}},{"id":740247,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":20926,"kind":"person","name":"Jones Keith Anthony","position":1,"cik":"0002026411","reported_name":"Jones Keith Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2026-06-12T21:55:38.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030."}],"balance_after":80000,"derivative":{"exercise_price":1.08,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001104659-26-073613","document":"tm2617880-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2026411/000110465926073613/tm2617880-6_4seq1.xml","form_type":"4"}},{"id":740151,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38824,"kind":"person","name":"Wallace Max N.","position":1,"cik":"0001877453","reported_name":"Wallace Max N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2026-06-12T17:58:46.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030."}],"balance_after":80000,"derivative":{"exercise_price":1.08,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001104659-26-073616","document":"tm2617880-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1877453/000110465926073616/tm2617880-9_4seq1.xml","form_type":"4"}},{"id":740162,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Stock Options (right to buy)","published_at":"2026-06-12T17:57:52.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030."}],"balance_after":80000,"derivative":{"exercise_price":1.08,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001104659-26-073615","document":"tm2617880-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000110465926073615/tm2617880-8_4seq1.xml","form_type":"4"}},{"id":740208,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38846,"kind":"person","name":"Green Charles Bruce","position":1,"cik":"0001945398","reported_name":"Green Charles Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2026-06-12T17:54:37.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030."}],"balance_after":80000,"derivative":{"exercise_price":1.08,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001104659-26-073611","document":"tm2617880-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1945398/000110465926073611/tm2617880-5_4seq1.xml","form_type":"4"}},{"id":740198,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38842,"kind":"person","name":"Seimetz Diane","position":1,"cik":"0001930980","reported_name":"Seimetz Diane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2026-06-12T17:53:28.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030."}],"balance_after":80000,"derivative":{"exercise_price":1.08,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001104659-26-073610","document":"tm2617880-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1930980/000110465926073610/tm2617880-4_4seq1.xml","form_type":"4"}},{"id":740248,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38862,"kind":"person","name":"Bamforth John Philip","position":1,"cik":"0002026341","reported_name":"Bamforth John Philip","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2026-06-12T17:52:30.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030."}],"balance_after":80000,"derivative":{"exercise_price":1.08,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001104659-26-073609","document":"tm2617880-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2026341/000110465926073609/tm2617880-3_4seq1.xml","form_type":"4"}},{"id":740163,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38830,"kind":"person","name":"Brown Emery N.","position":1,"cik":"0001878691","reported_name":"Brown Emery N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2026-06-12T17:51:31.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030."}],"balance_after":80000,"derivative":{"exercise_price":1.08,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001104659-26-073608","document":"tm2617880-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878691/000110465926073608/tm2617880-2_4seq1.xml","form_type":"4"}},{"id":740159,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38828,"kind":"person","name":"Dougan Brady W","position":1,"cik":"0001878020","reported_name":"Dougan Brady W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2026-06-12T17:50:13.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030."}],"balance_after":0,"derivative":{"exercise_price":1.08,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001104659-26-073607","document":"tm2617880-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878020/000110465926073607/tm2617880-1_4seq1.xml","form_type":"4"}},{"id":770128,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-20T20:33:09.000Z","date":"2026-05-19","kind":"purchase","planned":false,"acquired":true,"shares":56818,"price":0.88,"value":49999.84,"ownership":{"direct":true},"balance_after":148025,"source":{"system":"sec-edgar","filing":"0001654316-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000165431626000002/ownership.xml","form_type":"4"}},{"id":770127,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38798,"kind":"person","name":"Constantino Michael T.","position":1,"cik":"0001817285","reported_name":"Constantino Michael T.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-20T20:32:09.000Z","date":"2026-05-18","kind":"purchase","planned":false,"acquired":true,"shares":11000,"price":0.8945,"value":9839.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.8922 to $0.8958. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":43950,"source":{"system":"sec-edgar","filing":"0001817285-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181728526000002/ownership.xml","form_type":"4"}},{"id":770191,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":45705,"kind":"person","name":"Sander Dale A.","position":1,"cik":"0001878193","reported_name":"Sander Dale A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Chief Corp. Dev. Off"}}],"security":"Common Stock","published_at":"2026-05-20T20:31:20.000Z","date":"2026-05-18","kind":"sale","planned":true,"acquired":false,"shares":45887,"price":0.8967,"value":41146.8729,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the number of shares of Common Stock sold under an automated program to cover the statutory tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person.  This sale was mandated by the Issuer's practice to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell-to-cover\" transaction pursuant to a plan entered into by the Reporting Person for the purchase or sale of equity securities of the Issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), and therefore does not represent a discretionary sale by the Reporting Person."}],"balance_after":267213,"source":{"system":"sec-edgar","filing":"0001878193-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878193/000187819326000002/ownership.xml","form_type":"4"}},{"id":770126,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":45697,"kind":"person","name":"Parikh Shamik J","position":1,"cik":"0001916853","reported_name":"Parikh Shamik J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-20T20:30:31.000Z","date":"2026-05-18","kind":"sale","planned":true,"acquired":false,"shares":45887,"price":0.8967,"value":41146.8729,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the number of shares of Common Stock sold under an automated program to cover the statutory tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person.  This sale was mandated by the Issuer's practice to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell-to-cover\" transaction pursuant to a plan entered into by the Reporting Person for the purchase or sale of equity securities of the Issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), and therefore does not represent a discretionary sale by the Reporting Person."}],"balance_after":272713,"source":{"system":"sec-edgar","filing":"0001916853-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000191685326000002/ownership.xml","form_type":"4"}},{"id":997951,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":45705,"kind":"person","name":"Sander Dale A.","position":1,"cik":"0001878193","reported_name":"Sander Dale A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Chief Corp. Deve. Off."}}],"security":"Common Stock","published_at":"2025-11-17T22:52:29.000Z","date":"2025-11-16","kind":"grant","planned":false,"acquired":true,"shares":311100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Reporting Person was granted restricted stock units (RSUs), which represent a contingent right to receive one share of Common Stock for each RSU. The first 50% of the RSUs will vest on May 15, 2026, after which the remaining 50% of the RSUs will vest on May 15, 2027."}],"balance_after":313100,"source":{"system":"sec-edgar","filing":"0001628280-25-052723","document":"wk-form4_1763419946.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878193/000162828025052723/wk-form4_1763419946.xml","form_type":"4"}},{"id":997891,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":45697,"kind":"person","name":"Parikh Shamik J","position":1,"cik":"0001916853","reported_name":"Parikh Shamik J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-11-17T22:51:24.000Z","date":"2025-11-16","kind":"grant","planned":false,"acquired":true,"shares":311100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Reporting Person was granted restricted stock units (RSUs), which represent a contingent right to receive one share of Common Stock for each RSU. The first 50% of the RSUs will vest on May 15, 2026, after which the remaining 50% of the RSUs will vest on May 15, 2027."}],"balance_after":318600,"source":{"system":"sec-edgar","filing":"0001628280-25-052720","document":"wk-form4_1763419881.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000162828025052720/wk-form4_1763419881.xml","form_type":"4"}},{"id":997950,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38828,"kind":"person","name":"Dougan Brady W","position":1,"cik":"0001878020","reported_name":"Dougan Brady W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2025-11-17T17:49:56.000Z","date":"2025-11-16","kind":"grant","planned":false,"acquired":true,"shares":311100,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 1/3 of the option becomes exercisable on February 14, 2026, after which 1/3 of the option will become exercisable on November 16, 2026, and the remaining 1/3 of the option will become exercisable on November 16, 2027."}],"balance_after":311100,"derivative":{"exercise_price":1.23,"expiration_date":"2035-11-16","underlying":"Common Stock","underlying_shares":311100},"source":{"system":"sec-edgar","filing":"0001628280-25-052717","document":"wk-form4_1763419793.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878020/000162828025052717/wk-form4_1763419793.xml","form_type":"4"}},{"id":997952,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Stock Options (right to buy)","published_at":"2025-11-17T17:48:26.000Z","date":"2025-11-16","kind":"grant","planned":false,"acquired":true,"shares":311100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 1/3 of the option becomes exercisable on February 14, 2026, after which 1/3 of the option will become exercisable on November 16, 2026, and the remaining 1/3 of the option will become exercisable on November 16, 2027."}],"balance_after":311100,"derivative":{"exercise_price":1.23,"expiration_date":"2035-11-16","underlying":"Common Stock","underlying_shares":311100},"source":{"system":"sec-edgar","filing":"0001628280-25-052715","document":"wk-form4_1763419703.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000162828025052715/wk-form4_1763419703.xml","form_type":"4"}},{"id":1060413,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38828,"kind":"person","name":"Dougan Brady W","position":1,"cik":"0001878020","reported_name":"Dougan Brady W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-20T19:30:47.000Z","date":"2025-08-20","kind":"sale","planned":false,"acquired":false,"shares":591685,"price":1.58,"value":934862.3,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $1.53 to $1.69. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-25-081009","document":"tm2524042-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1878020/000110465925081009/tm2524042-2_4seq1.xml","form_type":"4"}},{"id":1060412,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38828,"kind":"person","name":"Dougan Brady W","position":1,"cik":"0001878020","reported_name":"Dougan Brady W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-20T19:30:47.000Z","date":"2025-08-19","kind":"sale","planned":false,"acquired":false,"shares":1100000,"price":1.63,"value":1793000.0,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $1.57 to $1.76. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":591685,"source":{"system":"sec-edgar","filing":"0001104659-25-081009","document":"tm2524042-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1878020/000110465925081009/tm2524042-2_4seq1.xml","form_type":"4"}},{"id":1060411,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38828,"kind":"person","name":"Dougan Brady W","position":1,"cik":"0001878020","reported_name":"Dougan Brady W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-20T19:30:47.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":549360,"price":1.83,"value":1005328.8,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $1.79 to $1.92. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1691685,"source":{"system":"sec-edgar","filing":"0001104659-25-081009","document":"tm2524042-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878020/000110465925081009/tm2524042-2_4seq1.xml","form_type":"4"}},{"id":1060419,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2025-08-20T19:29:04.000Z","date":"2025-08-20","kind":"sale","planned":false,"acquired":false,"shares":591685,"price":1.58,"value":934862.3,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $1.53 to $1.69. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-25-081008","document":"tm2524042-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000110465925081008/tm2524042-1_4seq1.xml","form_type":"4"}},{"id":1060418,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2025-08-20T19:29:04.000Z","date":"2025-08-19","kind":"sale","planned":false,"acquired":false,"shares":1100000,"price":1.63,"value":1793000.0,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $1.57 to $1.76. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":591685,"source":{"system":"sec-edgar","filing":"0001104659-25-081008","document":"tm2524042-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000110465925081008/tm2524042-1_4seq1.xml","form_type":"4"}},{"id":1060417,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2025-08-20T19:29:04.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":549360,"price":1.83,"value":1005328.8,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $1.79 to $1.92. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1691685,"source":{"system":"sec-edgar","filing":"0001104659-25-081008","document":"tm2524042-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000110465925081008/tm2524042-1_4seq1.xml","form_type":"4"}},{"id":1109876,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":78444,"kind":"person","name":"Pope Todd","position":1,"cik":"0001584367","reported_name":"Pope Todd","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2025-06-16T20:32:48.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on June 12, 2026, after which 1/48 of the option will become exercisable on the 12th of each month through June 12, 2029."}],"balance_after":80000,"derivative":{"exercise_price":2.41,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001818382-25-000118","document":"wk-form4_1750105960.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838225000118/wk-form4_1750105960.xml","form_type":"4"}},{"id":1110076,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":20926,"kind":"person","name":"Jones Keith Anthony","position":1,"cik":"0002026411","reported_name":"Jones Keith Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2025-06-16T20:32:22.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on June 12, 2026, after which 1/48 of the option will become exercisable on the 12th of each month through June 12, 2029."}],"balance_after":80000,"derivative":{"exercise_price":2.41,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001818382-25-000116","document":"wk-form4_1750105933.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2026411/000181838225000116/wk-form4_1750105933.xml","form_type":"4"}},{"id":1109875,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38799,"kind":"person","name":"Windham-Bannister Susan Richards","position":1,"cik":"0001713760","reported_name":"Windham-Bannister Susan Richards","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2025-06-16T20:31:56.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on June 12, 2026, after which 1/48 of the option will become exercisable on the 12th of each month through June 12, 2029."}],"balance_after":80000,"derivative":{"exercise_price":2.41,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001818382-25-000114","document":"wk-form4_1750105909.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838225000114/wk-form4_1750105909.xml","form_type":"4"}},{"id":1109874,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38798,"kind":"person","name":"Constantino Michael T.","position":1,"cik":"0001817285","reported_name":"Constantino Michael T.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2025-06-16T20:31:09.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on June 12, 2026, after which 1/48 of the option will become exercisable on the 12th of each month through June 12, 2029."}],"balance_after":80000,"derivative":{"exercise_price":2.41,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001818382-25-000110","document":"wk-form4_1750105863.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838225000110/wk-form4_1750105863.xml","form_type":"4"}},{"id":1109873,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2025-06-16T20:30:36.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on June 12, 2026, after which 1/48 of the option will become exercisable on the 12th of each month through June 12, 2029."}],"balance_after":80000,"derivative":{"exercise_price":2.41,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001818382-25-000107","document":"wk-form4_1750105821.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838225000107/wk-form4_1750105821.xml","form_type":"4"}},{"id":1109975,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38830,"kind":"person","name":"Brown Emery N.","position":1,"cik":"0001878691","reported_name":"Brown Emery N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2025-06-16T16:32:36.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on June 12, 2026, after which 1/48 of the option will become exercisable on the 12th of each month through June 12, 2029."}],"balance_after":80000,"derivative":{"exercise_price":2.41,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001818382-25-000117","document":"wk-form4_1750105947.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878691/000181838225000117/wk-form4_1750105947.xml","form_type":"4"}},{"id":1109969,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38824,"kind":"person","name":"Wallace Max N.","position":1,"cik":"0001877453","reported_name":"Wallace Max N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2025-06-16T16:32:08.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on June 12, 2026, after which 1/48 of the option will become exercisable on the 12th of each month through June 12, 2029."}],"balance_after":80000,"derivative":{"exercise_price":2.41,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001818382-25-000115","document":"wk-form4_1750105920.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1877453/000181838225000115/wk-form4_1750105920.xml","form_type":"4"}},{"id":1109972,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Stock Options (right to buy)","published_at":"2025-06-16T16:31:44.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The first 25% of the option becomes exercisable on  June 12, 2026, after which 1/48 of the option will become exercisable on the 12th of each month through June 12, 2029."}],"balance_after":0,"derivative":{"exercise_price":2.41,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001818382-25-000113","document":"wk-form4_1750105897.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838225000113/wk-form4_1750105897.xml","form_type":"4"}},{"id":1109971,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38828,"kind":"person","name":"Dougan Brady W","position":1,"cik":"0001878020","reported_name":"Dougan Brady W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2025-06-16T16:31:32.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The first 25% of the option becomes exercisable on June 12, 2026, after which 1/48 of the option will become exercisable on the 12th of each month through June 12, 2029."}],"balance_after":0,"derivative":{"exercise_price":2.41,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001818382-25-000112","document":"wk-form4_1750105886.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1878020/000181838225000112/wk-form4_1750105886.xml","form_type":"4"}},{"id":1110006,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38846,"kind":"person","name":"Green Charles Bruce","position":1,"cik":"0001945398","reported_name":"Green Charles Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2025-06-16T16:31:21.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on June 12, 2026, after which 1/48 of the option will become exercisable on the 12th of each month through June 12, 2029."}],"balance_after":80000,"derivative":{"exercise_price":2.41,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001818382-25-000111","document":"wk-form4_1750105874.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1945398/000181838225000111/wk-form4_1750105874.xml","form_type":"4"}},{"id":1110077,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38862,"kind":"person","name":"Bamforth John Philip","position":1,"cik":"0002026341","reported_name":"Bamforth John Philip","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2025-06-16T16:30:58.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on June 12, 2026, after which 1/48 of the option will become exercisable on the 12th of each month through June 12, 2029."}],"balance_after":80000,"derivative":{"exercise_price":2.41,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001818382-25-000109","document":"wk-form4_1750105851.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2026341/000181838225000109/wk-form4_1750105851.xml","form_type":"4"}},{"id":1110000,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38842,"kind":"person","name":"Seimetz Diane","position":1,"cik":"0001930980","reported_name":"Seimetz Diane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2025-06-16T16:30:47.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on June 12, 2026, after which 1/48 of the option will become exercisable on the 12th of each month through June 12, 2029."}],"balance_after":80000,"derivative":{"exercise_price":2.41,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001818382-25-000108","document":"wk-form4_1750105839.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1930980/000181838225000108/wk-form4_1750105839.xml","form_type":"4"}},{"id":1171903,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":80787,"kind":"person","name":"Scheessele William John","position":1,"cik":"0001879378","reported_name":"Scheessele William John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-04-15T16:03:35.000Z","date":"2025-04-14","kind":"purchase","planned":false,"acquired":true,"shares":6493,"price":1.54,"value":9999.22,"ownership":{"direct":true},"balance_after":22018,"source":{"system":"sec-edgar","filing":"0001818382-25-000052","document":"wk-form4_1744747408.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1879378/000181838225000052/wk-form4_1744747408.xml","form_type":"4"}},{"id":1172680,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":45705,"kind":"person","name":"Sander Dale A.","position":1,"cik":"0001878193","reported_name":"Sander Dale A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Chief Corp. Deve. Off."}}],"security":"Common Stock","published_at":"2025-04-14T13:00:23.000Z","date":"2025-04-10","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":1.53,"value":30600.0,"ownership":{"direct":false,"nature":"By spouse"},"balance_after":40600,"source":{"system":"sec-edgar","filing":"0001818382-25-000050","document":"wk-form4_1744635615.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878193/000181838225000050/wk-form4_1744635615.xml","form_type":"4"}},{"id":1172635,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":45697,"kind":"person","name":"Parikh Shamik J","position":1,"cik":"0001916853","reported_name":"Parikh Shamik J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-04-14T13:00:12.000Z","date":"2025-04-10","kind":"purchase","planned":false,"acquired":true,"shares":7500,"price":1.55,"value":11625.0,"ownership":{"direct":true},"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001818382-25-000049","document":"wk-form4_1744635605.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838225000049/wk-form4_1744635605.xml","form_type":"4"}},{"id":1175701,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-08T20:15:54.000Z","date":"2025-04-08","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":1.32,"value":66000.0,"ownership":{"direct":true},"balance_after":91207,"source":{"system":"sec-edgar","filing":"0001818382-25-000046","document":"wk-form4_1744143346.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838225000046/wk-form4_1744143346.xml","form_type":"4"}},{"id":1175700,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38798,"kind":"person","name":"Constantino Michael T.","position":1,"cik":"0001817285","reported_name":"Constantino Michael T.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-08T20:15:32.000Z","date":"2025-04-07","kind":"purchase","planned":false,"acquired":true,"shares":16000,"price":1.26,"value":20160.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $1.255 to $1.26. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":32950,"source":{"system":"sec-edgar","filing":"0001818382-25-000044","document":"wk-form4_1744143324.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838225000044/wk-form4_1744143324.xml","form_type":"4"}},{"id":1175765,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38846,"kind":"person","name":"Green Charles Bruce","position":1,"cik":"0001945398","reported_name":"Green Charles Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-08T16:15:44.000Z","date":"2025-04-08","kind":"purchase","planned":false,"acquired":true,"shares":6000,"price":1.29,"value":7740.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $1.285 to $1.2891. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":8400,"source":{"system":"sec-edgar","filing":"0001818382-25-000045","document":"wk-form4_1744143336.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1945398/000181838225000045/wk-form4_1744143336.xml","form_type":"4"}},{"id":1296469,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":83930,"kind":"person","name":"Cao Yang","position":1,"cik":"0001946538","reported_name":"Cao Yang","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Stock Options (right to buy)","published_at":"2025-01-23T21:34:47.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":283101,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on January 21, 2026, after which 1/48 of the option will become exercisable on the 21st of each month through  January 21, 2029."}],"balance_after":283101,"derivative":{"exercise_price":4.56,"expiration_date":"2035-01-21","underlying":"Common Stock","underlying_shares":283101},"source":{"system":"sec-edgar","filing":"0001818382-25-000019","document":"wk-form4_1737668079.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838225000019/wk-form4_1737668079.xml","form_type":"4"}},{"id":1296531,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":45705,"kind":"person","name":"Sander Dale A.","position":1,"cik":"0001878193","reported_name":"Sander Dale A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Chief Corp. Deve. Off."}}],"security":"Stock Options (right to buy)","published_at":"2025-01-23T21:34:14.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":283101,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on January 21, 2026, after which 1/48 of the option will become exercisable on the 21st of each month through  January 21, 2029."}],"balance_after":283101,"derivative":{"exercise_price":4.56,"expiration_date":"2035-01-21","underlying":"Common Stock","underlying_shares":283101},"source":{"system":"sec-edgar","filing":"0001818382-25-000016","document":"wk-form4_1737668047.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878193/000181838225000016/wk-form4_1737668047.xml","form_type":"4"}},{"id":1296470,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":45697,"kind":"person","name":"Parikh Shamik J","position":1,"cik":"0001916853","reported_name":"Parikh Shamik J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Options (right to buy)","published_at":"2025-01-23T21:34:03.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":283101,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on January 21, 2026, after which 1/48 of the option will become exercisable on the 21st of each month through  January 21, 2029."}],"balance_after":283101,"derivative":{"exercise_price":4.56,"expiration_date":"2035-01-21","underlying":"Common Stock","underlying_shares":283101},"source":{"system":"sec-edgar","filing":"0001818382-25-000015","document":"wk-form4_1737668036.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838225000015/wk-form4_1737668036.xml","form_type":"4"}},{"id":1296529,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":83932,"kind":"person","name":"Prichard Heather Ledbetter","position":1,"cik":"0001877712","reported_name":"Prichard Heather Ledbetter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options (right to buy)","published_at":"2025-01-23T16:35:11.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":283101,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on January 21, 2026, after which 1/48 of the option will become exercisable on the 21st of each month through  January 21, 2029."}],"balance_after":283101,"derivative":{"exercise_price":4.56,"expiration_date":"2035-01-21","underlying":"Common Stock","underlying_shares":283101},"source":{"system":"sec-edgar","filing":"0001818382-25-000021","document":"wk-form4_1737668104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1877712/000181838225000021/wk-form4_1737668104.xml","form_type":"4"}},{"id":1296534,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":80787,"kind":"person","name":"Scheessele William John","position":1,"cik":"0001879378","reported_name":"Scheessele William John","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Options (right to buy)","published_at":"2025-01-23T16:34:58.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":283101,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on January 21, 2026, after which 1/48 of the option will become exercisable on the 21st of each month through  January 21, 2029."}],"balance_after":283101,"derivative":{"exercise_price":4.56,"expiration_date":"2035-01-21","underlying":"Common Stock","underlying_shares":283101},"source":{"system":"sec-edgar","filing":"0001818382-25-000020","document":"wk-form4_1737668091.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1879378/000181838225000020/wk-form4_1737668091.xml","form_type":"4"}},{"id":1296530,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38828,"kind":"person","name":"Dougan Brady W","position":1,"cik":"0001878020","reported_name":"Dougan Brady W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2025-01-23T16:34:36.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":1130311,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on January 21, 2026, after which 1/48 of the option will become exercisable on the 21st of each month through  January 21, 2029."}],"balance_after":1130311,"derivative":{"exercise_price":4.56,"expiration_date":"2035-01-21","underlying":"Common Stock","underlying_shares":1130311},"source":{"system":"sec-edgar","filing":"0001818382-25-000018","document":"wk-form4_1737668069.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878020/000181838225000018/wk-form4_1737668069.xml","form_type":"4"}},{"id":1296533,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Stock Options (right to buy)","published_at":"2025-01-23T16:34:25.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":1130311,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on January 21, 2026, after which 1/48 of the option will become exercisable on the 21st of each month through  January 21, 2029."}],"balance_after":1130311,"derivative":{"exercise_price":4.56,"expiration_date":"2035-01-21","underlying":"Common Stock","underlying_shares":1130311},"source":{"system":"sec-edgar","filing":"0001818382-25-000017","document":"wk-form4_1737668058.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838225000017/wk-form4_1737668058.xml","form_type":"4"}},{"id":1324316,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":45705,"kind":"person","name":"Sander Dale A.","position":1,"cik":"0001878193","reported_name":"Sander Dale A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Chief Corp. Deve. Off."}}],"security":"Stock Options (right to buy)","published_at":"2024-12-20T22:09:32.000Z","date":"2024-12-19","kind":"grant","planned":false,"acquired":true,"shares":525,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On December 14, 2020, Humacyte granted options to purchase 2,625 shares of common stock, which vested as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application (\"BLA\") to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Humacyte previously reported three-fifths of the option grant on a Form 4 filed on August 27, 2021 and one-fifth of the option grant on a Form 4 filed on December 12, 2023. On December 19, 2024, Humacyte received FDA approval for its acellular tissue engineered vessel product candidate for an indication in vascular trauma. Accordingly, columns 5 and 7 of Table II report the number of securities equal to the final one-fifth of the 12/14/2020 option grant."}],"balance_after":2625,"derivative":{"exercise_price":10.28,"exercise_date":"2024-12-19","expiration_date":"2030-12-14","underlying":"Common Stock","underlying_shares":525},"source":{"system":"sec-edgar","filing":"0001818382-24-000230","document":"wk-form4_1734732566.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878193/000181838224000230/wk-form4_1734732566.xml","form_type":"4"}},{"id":1324317,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Stock Options (right to buy)","published_at":"2024-12-20T17:09:42.000Z","date":"2024-12-19","kind":"grant","planned":false,"acquired":true,"shares":525,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On December 14, 2020, Humacyte granted options to purchase 2,625 shares of common stock, which vested as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application (\"BLA\") to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Humacyte previously reported three-fifths of the option grant on a Form 4 filed on August 27, 2021 and one-fifth of the option grant on a Form 4 filed on December 12, 2023. On December 19, 2024, Humacyte received FDA approval for its acellular tissue engineered vessel product candidate for an indication in vascular trauma. Accordingly, columns 5 and 7 of Table II report the number of securities equal to the final one-fifth of the 12/14/2020 option grant."}],"balance_after":2625,"derivative":{"exercise_price":10.28,"exercise_date":"2024-12-19","expiration_date":"2030-12-14","underlying":"Common Stock","underlying_shares":525},"source":{"system":"sec-edgar","filing":"0001818382-24-000231","document":"wk-form4_1734732576.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838224000231/wk-form4_1734732576.xml","form_type":"4"}},{"id":1324314,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":83932,"kind":"person","name":"Prichard Heather Ledbetter","position":1,"cik":"0001877712","reported_name":"Prichard Heather Ledbetter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Options (right to buy)","published_at":"2024-12-20T17:09:22.000Z","date":"2024-12-19","kind":"grant","planned":false,"acquired":true,"shares":525,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On December 14, 2020, Humacyte granted options to purchase 2,625 shares of common stock, which vested as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application (\"BLA\") to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Humacyte previously reported three-fifths of the option grant on a Form 4 filed on August 27, 2021 and one-fifth of the option grant on a Form 4 filed on December 12, 2023. On December 19, 2024, Humacyte received FDA approval for its acellular tissue engineered vessel product candidate for an indication in vascular trauma. Accordingly, columns 5 and 7 of Table II report the number of securities equal to the final one-fifth of the 12/14/2020 option grant."}],"balance_after":2625,"derivative":{"exercise_price":10.28,"exercise_date":"2024-12-19","expiration_date":"2030-12-14","underlying":"Common Stock","underlying_shares":525},"source":{"system":"sec-edgar","filing":"0001818382-24-000229","document":"wk-form4_1734732556.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1877712/000181838224000229/wk-form4_1734732556.xml","form_type":"4"}},{"id":1324315,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38828,"kind":"person","name":"Dougan Brady W","position":1,"cik":"0001878020","reported_name":"Dougan Brady W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2024-12-20T17:09:12.000Z","date":"2024-12-19","kind":"grant","planned":false,"acquired":true,"shares":525,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On December 14, 2020, Humacyte granted options to purchase 2,625 shares of common stock, which vested as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application (\"BLA\") to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Humacyte previously reported three-fifths of the option grant on a Form 4 filed on August 27, 2021 and one-fifth of the option grant on a Form 4 filed on December 12, 2023. On December 19, 2024, Humacyte received FDA approval for its acellular tissue engineered vessel product candidate for an indication in vascular trauma. Accordingly, columns 5 and 7 of Table II report the number of securities equal to the final one-fifth of the 12/14/2020 option grant."}],"balance_after":2625,"derivative":{"exercise_price":10.28,"exercise_date":"2024-12-19","expiration_date":"2030-12-14","underlying":"Common Stock","underlying_shares":525},"source":{"system":"sec-edgar","filing":"0001818382-24-000228","document":"wk-form4_1734732546.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878020/000181838224000228/wk-form4_1734732546.xml","form_type":"4"}},{"id":1343151,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38798,"kind":"person","name":"Constantino Michael T.","position":1,"cik":"0001817285","reported_name":"Constantino Michael T.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-04T21:05:50.000Z","date":"2024-12-04","kind":"purchase","planned":false,"acquired":true,"shares":4600,"price":4.3872,"value":20181.12,"ownership":{"direct":true},"balance_after":16950,"source":{"system":"sec-edgar","filing":"0001818382-24-000216","document":"wk-form4_1733346343.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000216/wk-form4_1733346343.xml","form_type":"4"}},{"id":1355932,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2024-11-21T07:31:17.000Z","date":"2024-11-19","kind":"purchase","planned":false,"acquired":true,"shares":1797,"price":4.44,"value":7978.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This purchase is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the sale by Ayabudge LLC, an entity controlled by the Reporting Person's spouse, of 809,786 shares of the Issuer's common stock on May 31, 2024. The Reporting Person has paid the Issuer $8,778.23, representing the full amount of profit realized in connection with this purchase."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $4.435 to $4.4352. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":243851,"source":{"system":"sec-edgar","filing":"0001818382-24-000214","document":"wk-form4_1732192270.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838224000214/wk-form4_1732192270.xml","form_type":"4"}},{"id":1355931,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38828,"kind":"person","name":"Dougan Brady W","position":1,"cik":"0001878020","reported_name":"Dougan Brady W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-21T07:30:16.000Z","date":"2024-11-19","kind":"purchase","planned":false,"acquired":true,"shares":1797,"price":4.44,"value":7978.68,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This purchase by the Reporting Person's spouse is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the sale by Ayabudge LLC, an entity controlled by the Reporting Person, of 809,786 shares of the Issuer's common stock on May 31, 2024. The Reporting Person's spouse has paid the Issuer $8,778.23, representing the full amount of profit realized in connection with this purchase."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $4.435 to $4.4352. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":243851,"source":{"system":"sec-edgar","filing":"0001818382-24-000213","document":"wk-form4_1732192208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878020/000181838224000213/wk-form4_1732192208.xml","form_type":"4"}},{"id":1357428,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2024-11-20T19:06:35.000Z","date":"2024-11-20","kind":"sale","planned":false,"acquired":false,"shares":261369,"price":4.4,"value":1150023.6,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.29 to $4.54. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1730884,"source":{"system":"sec-edgar","filing":"0001818382-24-000208","document":"wk-form4_1732147588.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838224000208/wk-form4_1732147588.xml","form_type":"4"}},{"id":1357427,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2024-11-20T19:06:35.000Z","date":"2024-11-19","kind":"sale","planned":false,"acquired":false,"shares":427459,"price":4.34,"value":1855172.06,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.15 to $4.455. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1992253,"source":{"system":"sec-edgar","filing":"0001818382-24-000208","document":"wk-form4_1732147588.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838224000208/wk-form4_1732147588.xml","form_type":"4"}},{"id":1357426,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2024-11-20T19:06:35.000Z","date":"2024-11-18","kind":"sale","planned":false,"acquired":false,"shares":811172,"price":4.44,"value":3601603.68,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.26 to $4.62. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":2419712,"source":{"system":"sec-edgar","filing":"0001818382-24-000208","document":"wk-form4_1732147588.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838224000208/wk-form4_1732147588.xml","form_type":"4"}},{"id":1357425,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38828,"kind":"person","name":"Dougan Brady W","position":1,"cik":"0001878020","reported_name":"Dougan Brady W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-20T19:02:25.000Z","date":"2024-11-20","kind":"sale","planned":false,"acquired":false,"shares":261369,"price":4.4,"value":1150023.6,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.29 to $4.54. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1730884,"source":{"system":"sec-edgar","filing":"0001818382-24-000206","document":"wk-form4_1732147338.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1878020/000181838224000206/wk-form4_1732147338.xml","form_type":"4"}},{"id":1357424,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38828,"kind":"person","name":"Dougan Brady W","position":1,"cik":"0001878020","reported_name":"Dougan Brady W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-20T19:02:25.000Z","date":"2024-11-19","kind":"sale","planned":false,"acquired":false,"shares":427459,"price":4.34,"value":1855172.06,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.15 to $4.455. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1992253,"source":{"system":"sec-edgar","filing":"0001818382-24-000206","document":"wk-form4_1732147338.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1878020/000181838224000206/wk-form4_1732147338.xml","form_type":"4"}},{"id":1357423,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38828,"kind":"person","name":"Dougan Brady W","position":1,"cik":"0001878020","reported_name":"Dougan Brady W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-20T19:02:25.000Z","date":"2024-11-18","kind":"sale","planned":false,"acquired":false,"shares":811172,"price":4.44,"value":3601603.68,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.26 to $4.62. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":2419712,"source":{"system":"sec-edgar","filing":"0001818382-24-000206","document":"wk-form4_1732147338.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878020/000181838224000206/wk-form4_1732147338.xml","form_type":"4"}},{"id":1406824,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38846,"kind":"person","name":"Green Charles Bruce","position":1,"cik":"0001945398","reported_name":"Green Charles Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2024-09-16T16:36:52.000Z","date":"2024-09-13","kind":"exercise","planned":false,"acquired":false,"shares":1200,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":10600,"derivative":{"exercise_price":4.09,"exercise_date":"2023-09-15","expiration_date":"2032-09-15","underlying":"Common Stock","underlying_shares":1200},"source":{"system":"sec-edgar","filing":"0001818382-24-000189","document":"wk-form4_1726519004.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1945398/000181838224000189/wk-form4_1726519004.xml","form_type":"4"}},{"id":1406823,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38846,"kind":"person","name":"Green Charles Bruce","position":1,"cik":"0001945398","reported_name":"Green Charles Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-16T16:36:52.000Z","date":"2024-09-13","kind":"exercise","planned":false,"acquired":true,"shares":1200,"price":4.09,"value":4908.0,"ownership":{"direct":true},"balance_after":2400,"source":{"system":"sec-edgar","filing":"0001818382-24-000189","document":"wk-form4_1726519004.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1945398/000181838224000189/wk-form4_1726519004.xml","form_type":"4"}},{"id":1409837,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2024-09-11T21:53:12.000Z","date":"2024-09-10","kind":"exercise","planned":false,"acquired":false,"shares":2479,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6021,"derivative":{"exercise_price":3.35,"exercise_date":"2024-08-15","expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":2479},"source":{"system":"sec-edgar","filing":"0001818382-24-000186","document":"wk-form4_1726091586.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000186/wk-form4_1726091586.xml","form_type":"4"}},{"id":1409836,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2024-09-11T21:53:12.000Z","date":"2024-09-10","kind":"exercise","planned":false,"acquired":false,"shares":4521,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3979,"derivative":{"exercise_price":4.34,"exercise_date":"2024-08-09","expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":4521},"source":{"system":"sec-edgar","filing":"0001818382-24-000186","document":"wk-form4_1726091586.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000186/wk-form4_1726091586.xml","form_type":"4"}},{"id":1409835,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-11T21:53:12.000Z","date":"2024-09-10","kind":"sale","planned":false,"acquired":false,"shares":1548,"price":5.39,"value":8343.72,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $5.38 to $5.40. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":41207,"source":{"system":"sec-edgar","filing":"0001818382-24-000186","document":"wk-form4_1726091586.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000186/wk-form4_1726091586.xml","form_type":"4"}},{"id":1409834,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-11T21:53:12.000Z","date":"2024-09-10","kind":"exercise","planned":false,"acquired":true,"shares":2479,"price":3.35,"value":8304.65,"ownership":{"direct":true},"balance_after":42755,"source":{"system":"sec-edgar","filing":"0001818382-24-000186","document":"wk-form4_1726091586.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000186/wk-form4_1726091586.xml","form_type":"4"}},{"id":1409833,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-11T21:53:12.000Z","date":"2024-09-10","kind":"sale","planned":false,"acquired":false,"shares":3634,"price":5.41,"value":19659.94,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $5.411 to $5.42. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":40276,"source":{"system":"sec-edgar","filing":"0001818382-24-000186","document":"wk-form4_1726091586.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000186/wk-form4_1726091586.xml","form_type":"4"}},{"id":1409832,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-11T21:53:12.000Z","date":"2024-09-10","kind":"exercise","planned":false,"acquired":true,"shares":4521,"price":4.34,"value":19621.14,"ownership":{"direct":true},"balance_after":43910,"source":{"system":"sec-edgar","filing":"0001818382-24-000186","document":"wk-form4_1726091586.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000186/wk-form4_1726091586.xml","form_type":"4"}},{"id":1409883,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38828,"kind":"person","name":"Dougan Brady W","position":1,"cik":"0001878020","reported_name":"Dougan Brady W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-11T17:52:09.000Z","date":"2024-09-10","kind":"sale","planned":false,"acquired":false,"shares":288674,"price":5.23,"value":1509765.02,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $5.14 to $5.325. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":3230884,"source":{"system":"sec-edgar","filing":"0001818382-24-000185","document":"wk-form4_1726091522.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1878020/000181838224000185/wk-form4_1726091522.xml","form_type":"4"}},{"id":1409882,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38828,"kind":"person","name":"Dougan Brady W","position":1,"cik":"0001878020","reported_name":"Dougan Brady W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-11T17:52:09.000Z","date":"2024-09-09","kind":"sale","planned":false,"acquired":false,"shares":157704,"price":5.42,"value":854755.68,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $5.36 to $5.505. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":3519558,"source":{"system":"sec-edgar","filing":"0001818382-24-000185","document":"wk-form4_1726091522.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878020/000181838224000185/wk-form4_1726091522.xml","form_type":"4"}},{"id":1409885,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2024-09-11T17:50:36.000Z","date":"2024-09-10","kind":"sale","planned":false,"acquired":false,"shares":288674,"price":5.23,"value":1509765.02,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $5.14 to $5.325. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":3230884,"source":{"system":"sec-edgar","filing":"0001818382-24-000184","document":"wk-form4_1726091430.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838224000184/wk-form4_1726091430.xml","form_type":"4"}},{"id":1409884,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2024-09-11T17:50:36.000Z","date":"2024-09-09","kind":"sale","planned":false,"acquired":false,"shares":157704,"price":5.42,"value":854755.68,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $5.36 to $5.505. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":3519558,"source":{"system":"sec-edgar","filing":"0001818382-24-000184","document":"wk-form4_1726091430.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838224000184/wk-form4_1726091430.xml","form_type":"4"}},{"id":1417886,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2024-09-03T16:23:53.000Z","date":"2024-08-29","kind":"purchase","planned":false,"acquired":true,"shares":1222,"price":6.545,"value":7997.99,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This purchase is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the sale by Ayabudge LLC, an entity controlled by the Reporting Person's spouse, of 809,786 shares of the Issuer's common stock on May 31, 2024. The Reporting Person has paid the Issuer $3,391.05, representing the full amount of profit realized in connection with this purchase."}],"balance_after":242054,"source":{"system":"sec-edgar","filing":"0001818382-24-000177","document":"wk-form4_1725395025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838224000177/wk-form4_1725395025.xml","form_type":"4"}},{"id":1417885,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38828,"kind":"person","name":"Dougan Brady W","position":1,"cik":"0001878020","reported_name":"Dougan Brady W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-03T16:17:12.000Z","date":"2024-08-29","kind":"purchase","planned":false,"acquired":true,"shares":1222,"price":6.545,"value":7997.99,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This purchase by the Reporting Person's spouse is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the sale by Ayabudge LLC, an entity controlled by the Reporting Person, of 809,786 shares of the Issuer's common stock on May 31, 2024. The Reporting Person's spouse has paid the Issuer $3,391.05, representing the full amount of profit realized in connection with this purchase."}],"balance_after":242054,"source":{"system":"sec-edgar","filing":"0001818382-24-000175","document":"wk-form4_1725394624.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878020/000181838224000175/wk-form4_1725394624.xml","form_type":"4"}},{"id":1420037,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":45705,"kind":"person","name":"Sander Dale A.","position":1,"cik":"0001878193","reported_name":"Sander Dale A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Chief Corp. Deve. Off."}}],"security":"Stock Options (right to buy)","published_at":"2024-08-29T22:45:12.000Z","date":"2024-08-27","kind":"exercise","planned":false,"acquired":false,"shares":39389,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":2.56,"exercise_date":"2018-09-01","expiration_date":"2025-09-01","underlying":"Common Stock","underlying_shares":39389},"source":{"system":"sec-edgar","filing":"0001818382-24-000165","document":"wk-form4_1724971323.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1878193/000181838224000165/wk-form4_1724971323.xml","form_type":"4"}},{"id":1420036,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":45705,"kind":"person","name":"Sander Dale A.","position":1,"cik":"0001878193","reported_name":"Sander Dale A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Chief Corp. Deve. Off."}}],"security":"Common Stock","published_at":"2024-08-29T22:45:12.000Z","date":"2024-08-27","kind":"sale","planned":false,"acquired":false,"shares":39389,"price":6.68,"value":263118.52,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $6.67 to $6.725. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":2000,"source":{"system":"sec-edgar","filing":"0001818382-24-000165","document":"wk-form4_1724971323.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1878193/000181838224000165/wk-form4_1724971323.xml","form_type":"4"}},{"id":1420035,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":45705,"kind":"person","name":"Sander Dale A.","position":1,"cik":"0001878193","reported_name":"Sander Dale A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and Chief Corp. Deve. Off."}}],"security":"Common Stock","published_at":"2024-08-29T22:45:12.000Z","date":"2024-08-27","kind":"exercise","planned":false,"acquired":true,"shares":39389,"price":2.56,"value":100835.84,"ownership":{"direct":true},"balance_after":41389,"source":{"system":"sec-edgar","filing":"0001818382-24-000165","document":"wk-form4_1724971323.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878193/000181838224000165/wk-form4_1724971323.xml","form_type":"4"}},{"id":1420033,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38828,"kind":"person","name":"Dougan Brady W","position":1,"cik":"0001878020","reported_name":"Dougan Brady W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-29T18:52:47.000Z","date":"2024-08-29","kind":"sale","planned":false,"acquired":false,"shares":352112,"price":6.35,"value":2235911.2,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $6.13 to $6.56. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":3677262,"source":{"system":"sec-edgar","filing":"0001818382-24-000167","document":"wk-form4_1724971784.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1878020/000181838224000167/wk-form4_1724971784.xml","form_type":"4"}},{"id":1420032,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38828,"kind":"person","name":"Dougan Brady W","position":1,"cik":"0001878020","reported_name":"Dougan Brady W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-29T18:52:47.000Z","date":"2024-08-28","kind":"sale","planned":false,"acquired":false,"shares":277090,"price":6.47,"value":1792772.3,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $6.36 to $6.60. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":4029374,"source":{"system":"sec-edgar","filing":"0001818382-24-000167","document":"wk-form4_1724971784.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1878020/000181838224000167/wk-form4_1724971784.xml","form_type":"4"}},{"id":1420031,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38828,"kind":"person","name":"Dougan Brady W","position":1,"cik":"0001878020","reported_name":"Dougan Brady W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-29T18:52:47.000Z","date":"2024-08-27","kind":"sale","planned":false,"acquired":false,"shares":252676,"price":6.71,"value":1695455.96,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $6.58 to $7.075. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":4306464,"source":{"system":"sec-edgar","filing":"0001818382-24-000167","document":"wk-form4_1724971784.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878020/000181838224000167/wk-form4_1724971784.xml","form_type":"4"}},{"id":1420040,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2024-08-29T18:48:06.000Z","date":"2024-08-29","kind":"sale","planned":false,"acquired":false,"shares":352112,"price":6.35,"value":2235911.2,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $6.13 to $6.56. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":3677262,"source":{"system":"sec-edgar","filing":"0001818382-24-000166","document":"wk-form4_1724971594.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838224000166/wk-form4_1724971594.xml","form_type":"4"}},{"id":1420039,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2024-08-29T18:48:06.000Z","date":"2024-08-28","kind":"sale","planned":false,"acquired":false,"shares":277090,"price":6.47,"value":1792772.3,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $6.36 to $6.60. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":4029374,"source":{"system":"sec-edgar","filing":"0001818382-24-000166","document":"wk-form4_1724971594.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838224000166/wk-form4_1724971594.xml","form_type":"4"}},{"id":1420038,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38829,"kind":"person","name":"Niklason Laura E","position":1,"cik":"0001878075","reported_name":"Niklason Laura E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO and Director"}}],"security":"Common Stock","published_at":"2024-08-29T18:48:06.000Z","date":"2024-08-27","kind":"sale","planned":false,"acquired":false,"shares":252676,"price":6.71,"value":1695455.96,"ownership":{"direct":false,"nature":"By Ayabudge LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $6.58 to $7.075. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":4306464,"source":{"system":"sec-edgar","filing":"0001818382-24-000166","document":"wk-form4_1724971594.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1878075/000181838224000166/wk-form4_1724971594.xml","form_type":"4"}},{"id":1432631,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38798,"kind":"person","name":"Constantino Michael T.","position":1,"cik":"0001817285","reported_name":"Constantino Michael T.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-15T20:08:27.000Z","date":"2024-08-15","kind":"purchase","planned":false,"acquired":true,"shares":3100,"price":6.2883,"value":19493.73,"ownership":{"direct":true},"balance_after":12350,"source":{"system":"sec-edgar","filing":"0001818382-24-000158","document":"wk-form4_1723752500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000158/wk-form4_1723752500.xml","form_type":"4"}},{"id":1477454,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2024-06-17T20:15:53.000Z","date":"2024-06-14","kind":"exercise","planned":false,"acquired":false,"shares":39389,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":2.56,"exercise_date":"2018-09-01","expiration_date":"2025-09-01","underlying":"Common Stock","underlying_shares":39389},"source":{"system":"sec-edgar","filing":"0001818382-24-000143","document":"wk-form4_1718655345.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000143/wk-form4_1718655345.xml","form_type":"4"}},{"id":1477453,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2024-06-17T20:15:53.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on June 13, 2025, after which 1/48 of the option will become exercisable on the 13th of each month through June 13, 2028."}],"balance_after":50000,"derivative":{"exercise_price":7.2,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001818382-24-000143","document":"wk-form4_1718655345.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000143/wk-form4_1718655345.xml","form_type":"4"}},{"id":1477452,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38797,"kind":"person","name":"Sebelius Kathleen","position":1,"cik":"0001654316","reported_name":"Sebelius Kathleen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-17T20:15:53.000Z","date":"2024-06-14","kind":"exercise","planned":false,"acquired":true,"shares":39389,"price":2.56,"value":100835.84,"ownership":{"direct":true},"balance_after":39389,"source":{"system":"sec-edgar","filing":"0001818382-24-000143","document":"wk-form4_1718655345.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000143/wk-form4_1718655345.xml","form_type":"4"}},{"id":1477451,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38799,"kind":"person","name":"Windham-Bannister Susan Richards","position":1,"cik":"0001713760","reported_name":"Windham-Bannister Susan Richards","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2024-06-17T20:12:56.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on June 13, 2025, after which 1/48 of the option will become exercisable on the 13th of each month through June 13, 2028."}],"balance_after":50000,"derivative":{"exercise_price":7.2,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001818382-24-000142","document":"wk-form4_1718655168.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000142/wk-form4_1718655168.xml","form_type":"4"}},{"id":1477450,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":78444,"kind":"person","name":"Pope Todd","position":1,"cik":"0001584367","reported_name":"Pope Todd","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2024-06-17T20:12:21.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on June 13, 2025, after which 1/48 of the option will become exercisable on the 13th of each month through June 13, 2028."}],"balance_after":50000,"derivative":{"exercise_price":7.2,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001818382-24-000139","document":"wk-form4_1718655133.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000139/wk-form4_1718655133.xml","form_type":"4"}},{"id":1477571,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":20926,"kind":"person","name":"Jones Keith Anthony","position":1,"cik":"0002026411","reported_name":"Jones Keith Anthony","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2024-06-17T20:11:58.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on June 13, 2025, after which 1/48 of the option will become exercisable on the 13th of each month through June 13, 2028."}],"balance_after":75000,"derivative":{"exercise_price":7.2,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001818382-24-000137","document":"wk-form4_1718655110.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2026411/000181838224000137/wk-form4_1718655110.xml","form_type":"4"}},{"id":1477449,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38798,"kind":"person","name":"Constantino Michael T.","position":1,"cik":"0001817285","reported_name":"Constantino Michael T.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2024-06-17T20:11:23.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on June 13, 2025, after which 1/48 of the option will become exercisable on the 13th of each month through June 13, 2028."}],"balance_after":50000,"derivative":{"exercise_price":7.2,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001818382-24-000134","document":"wk-form4_1718655077.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000134/wk-form4_1718655077.xml","form_type":"4"}},{"id":1477495,"issuer":{"id":6478,"kind":"organization","name":"Humacyte, Inc.","symbol":"HUMA"},"owners":[{"id":38824,"kind":"person","name":"Wallace Max N.","position":1,"cik":"0001877453","reported_name":"Wallace Max N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2024-06-17T16:12:43.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The first 25% of the option becomes exercisable on June 13, 2025, after which 1/48 of the option will become exercisable on the 13th of each month through June 13, 2028."}],"balance_after":50000,"derivative":{"exercise_price":7.2,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001818382-24-000141","document":"wk-form4_1718655156.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1877453/000181838224000141/wk-form4_1718655156.xml","form_type":"4"}}],"next_cursor":"2024-06-17T16:12:43.000000Z,1477495"}